Sagimet Biosciences (SGMT) announced the presentation of Phase 2b data demonstrating the anti-fibrotic activity of its fatty acid synthase ...
Subset analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis in difficult-to-treat MASH patientsBoth artificial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback